Ascletis Unveils Innovative Diabetes Treatments at ADA 2026 Conference

Ascletis Showcases Advances in Diabetes Treatment at ADA 2026

Ascletis Pharma Inc. will present a series of innovative programs at the upcoming American Diabetes Association (ADA) 2026 Scientific Sessions, scheduled from June 5 to 8 in New Orleans, Louisiana. This event is a critical platform for researchers and healthcare professionals to share significant findings in diabetes treatment, and Ascletis aims to make a considerable impact with its latest developments.

Among the highlighted presentations, Ascletis will feature a late-breaking poster detailing preclinical data on ASC39, a potent oral small molecule amylin receptor agonist designed to combat obesity. Amylin receptor agonists represent an exciting frontier in the management of metabolic disorders, offering a new method of addressing weight-related issues in diabetes care.

Presentation Overview

Ascletis will lead three poster presentations on June 7, 2026. Each presentation aims to shed light on the efficacy and safety of the company’s developing diabetes treatments:

1. ASC39: An Oral Small Molecule Amylin Receptor Agonist for Obesity Treatment
- Session: Late-Breaking Poster Session (3067-LB)
- Time: 12:30 PM CT
This presentation will focus on ASC39, which shows promise in its ability to aid weight management through its novel mechanism of action.

2. ASC30: Oral Small Molecule GLP-1 Demonstrated Significant Weight Loss
- Session: General Poster Session (1672-P)
- Time: 12:30 PM CT
This program will present data from a Phase II study showing that ASC30 achieved a placebo-adjusted weight loss of 7.7% in participants living with obesity, alongside improved gastrointestinal tolerability.

3. ASC37: GLP-1R/GIPR/GCGR Triple Agonist
- Session: General Poster Session (1673-P)
- Time: 12:30 PM CT
This presentation will highlight ASC37's capabilities, showcasing its average absolute oral bioavailability of 4.2% in studies conducted on nonhuman primates, underscoring its potential for effective delivery.

About Ascletis Pharma Inc.

Ascletis is a fully integrated biotechnology firm dedicated to discovering and developing cutting-edge therapeutics for metabolic diseases. The company employs advanced technologies, including its proprietary Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD) and Ultra-Long-Acting Platform (ULAP), to enhance the drug development process. Their ongoing research includes a range of compounds designed for effective oral ingestion and sustained treatment regimens for chronic weight management and other metabolic conditions.

Ascletis’ commitment to innovation places it at the forefront of battling diabetes and obesity, with a clear mission to provide effective solutions that improve patient outcomes. The company’s leading programs, such as ASC30 and ASC39, represent significant steps towards addressing the unmet needs of patients suffering from these challenging conditions.

For further insights on Ascletis’ innovative approaches and results from the ADA 2026, stakeholders can visit their official website at Ascletis Pharma. As the company continues to advance its promising research-based solutions, it remains a key player in the ongoing fight against diabetes-related challenges and obesity.